In the Ang II-induced hypertension model, ChAT administration dose-dependently reduces Ang II-induced elevation of MAP (Fig. 3C), SBP (Additional file 1: Fig. S1A) and DBP (Additional file 1: Fig. S1B), when measured as area-under-the-curve compared to baseline blood pressures. This evidence concerns the gene AGT and Hypertension.